Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US

被引：1
|
作者：
Petersen, Tonny Studsgaard [1 ,2 ]
Karstoft, Kristian [1 ,2 ]
Sorup, Freja Karuna Hemmingsen [1 ,2 ]
Lund, Marie [1 ,2 ,3 ]
Cramer, Allan [1 ]
机构：
[1] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Clin Pharmacol, Bispebjerg Bakke 23,2400 Kbh NV, DK-2400 Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark
来源：
JAMA ONCOLOGY | 2025年 / 11卷 / 01期
关键词：
D O I：
10.1001/jamaoncol.2024.5145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [41] Regulatory standards for environmental risks: Understanding the US-European union conflict over genetically modified crops
    Murphy, J
    Levidow, L
    Carr, S
    SOCIAL STUDIES OF SCIENCE, 2006, 36 (01) : 133 - 160
  • [42] The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer A Case of Regulatory Capture?
    Gyawali, Bishal
    Goldstein, Daniel A.
    JAMA ONCOLOGY, 2018, 4 (05) : 623 - 624
  • [43] Accelerated vs regular approval, differences in study characteristics of lung cancer treatments approved by the US Food and Drug Administration
    Ribeiro, Tatiane
    Buss, Lewis
    Ali, Sanni
    Nobre, Moacyr
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 163 - 163
  • [44] CHARACTERISTICS OF POSTMENOPAUSAL WOMEN INITIATING RALOXIFENE BEFORE AND AFTER APPROVAL OF INVASIVE BREAST CANCER RISK REDUCTION INDICATIONS
    Foster, S.
    McQuarrie, N.
    Coleman, A.
    Whangbo, A.
    Miller, L. A.
    Bhujabal, S.
    Gilra, N.
    VALUE IN HEALTH, 2010, 13 (03) : A51 - A52
  • [45] Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies
    Bonsu, Janice M.
    Kola-Kehinde, Onaopepo
    Kim, Lisa
    Ruz, Patrick
    Campbell, Courtney M.
    Brammer, Jonathan E.
    Addison, Daniel
    JAMA ONCOLOGY, 2021, 7 (11) : 1722 - 1723
  • [46] A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making
    Coppens, D. G. M.
    de Wilde, S.
    Guchelaar, H. J.
    De Bruin, M. L.
    Leufkens, H. G. M.
    Meij, P.
    Hoekman, J.
    CYTOTHERAPY, 2018, 20 (06) : 769 - 778
  • [47] PROTECTION OF TRADITIONAL PRODUCTS THROUGH GEOGRAPHICAL INDICATIONS IN THE EUROPEAN UNION AFTER THE ENTRY INTO FORCE OF THE GENEVA ACT OF THE LISBON AGREEMENT ON APPELLATIONS OF ORIGIN AND GEOGRAPHICAL INDICATIONS
    Hasic, Tea
    Marinkovic, Ana Racki
    PRAVNI VJESNIK, 2022, 38 (01): : 113 - 130
  • [48] Japan's conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA
    Murayama, Anju
    Ueda, Munetaka
    Shrestha, Sunil
    Tanimoto, Tetsuya
    Ozaki, Akihiko
    CANCER CELL, 2021, 39 (09) : 1165 - 1166
  • [49] Factors That Facilitate Regulatory Approval for Drug-Device Combination Products in the European Union and United States of America: A Mixed Method Study of Industry Views
    Fiona Masterson
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 489 - 498
  • [50] Factors That Facilitate Regulatory Approval for Drug-Device Combination Products in the European Union and United States of America: A Mixed Method Study of Industry Views
    Masterson, Fiona
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (04) : 489 - 498
12345